The device maker’s Switzerland-based vice president of rhythm management for Europe, the Middle East and Africa expects a “massive shift” to pulsed field ablation from other atrial fibrillation treatments.
The device maker’s Switzerland-based vice president of rhythm management for Europe, the Middle East and Africa expects a “massive shift” to pulsed field ablation from other atrial fibrillation treatments.